Figures & data
Figure 1. Study flow chart.
Table 1. Demographic characteristics of subjects enrolled in the prime-boost study
Figure 2. Serum antibody titers to A/17/turkey/Turkey/05/133 (H5N2) in volunteers before vaccination with A(H5N1) IIV (Day 0). Dots– individual data of volunteers vaccinated with H5N2 LAIV in 2012 (n=19), and non-vaccinated with LAIV in 2012 (n = 24); lines– Ab GMTs.P values were calculated using GraphPad Prism 5 software by Mann Whitney U test.
Table 2. Serum antibody (Ab) responses on days 7, 28 and 56 following administration of A(H5N1) inactivated influenza vaccine (IIV)
Table 3. Serum IgA and IgG immune responses in A(H5N2) LAIV-primed and control volunteers immunized with A(H5N1) IIV at indicated time points
Table 4. Avidity of serum IgA and IgG antibodies in A(H5N2) LAIV-primed and control subjects immunized with one dose of A(H5N1) IIV at indicated time points
Figure 3. Antibody titers in supernatants of PBMC cultures (ALS) in LAIV-primed (n = 19) and control (n = 24) volunteers at indicated study days after boost immunization with A(H5N1) IIV. (A) NIBRG-23 (H5N1) virus was used as antigen. (B) A/17/turkey/Turkey/05/133 (H5N2) virus was used as antigen. lines– geometric mean titers of antibodies. P values were calculated from log2-transformed titers using GraphPad Prism 5 software by Mann Whitney U test.
Table 5. CD8+ T-cell immune response in A(H5N2) LAIV-primed and control subjects immunized with A(H5N1) IIV at indicated time points